Early-stage non-small cell lung cancer: Surgery, stereotactic radiosurgery, and individualized adjuvant therapy

Seminars in Oncology

Volumn 41, Issue 1, 2014, Pages 40-56

  Padda, Sukhmani K ^a   Burt, Bryan M ^a   Trakul, Nicholas ^b   Wakelee, Heather A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; EARLY DETECTION OF CANCER; HUMANS; INDIVIDUALIZED MEDICINE; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; RADIOSURGERY; RADIOTHERAPY, ADJUVANT; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84894429089     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.12.011     Document Type: Article

References (125)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. P. Goldstraw, J. Crowley, K. Chansky, D.J. Giroux, P.A. Groome, and R. Rami-Porta et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours J Thorac Oncol 2 2007 706 714
3. W.J. Scott, J. Howington, S. Feigenberg, B. Movsas, and K. Pisters American College of Chest P. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition) Chest 132 2007 234S 242S
4. B.J. Park Is surgical morbidity decreased with minimally invasive lobectomy? Cancer J 17 2011 18 22
5. S. Paul, N.K. Altorki, S. Sheng, P.C. Lee, D.H. Harpole, and M.W. Onaitis et al. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database J Thorac Cardiovasc Surg 139 2010 366 378
6. N.R. Villamizar, M.D. Darrabie, W.R. Burfeind, R.P. Petersen, M.W. Onaitis, and E. Toloza et al. Thoracoscopic lobectomy is associated with lower morbidity compared with thoracotomy J Thorac Cardiovasc Surg 138 2009 419 425
7. F.C. Detterbeck, M.A. Jantz, M. Wallace, J. Vansteenkiste, and G.A. Silvestri American College of Chest P. Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition) Chest 132 2007 202S 220S
8. BW CJ Loo, L.A. Dawson, B.D. Kavanagh, A.C. Koong, S. Senan, and R.D. Timmerman Stereotactic ablative radiotherapy: what's in a name? Pract Radiat Oncol 1 2011 38 39
9. D.S. Ettinger, W. Akerley, H. Borghaei, A.C. Chang, R.T. Cheney, and L.R. Chirieac et al. Non-small cell lung cancer, version 2.2013 J Natl Compr Canc Netw 11 2013 645 653
10. E. Lim, G. Harris, A. Patel, I. Adachi, L. Edmonds, and F. Song Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials J Thorac Oncol 4 2009 1380 1388
11. G.V. Scagliotti, R. Fossati, V. Torri, L. Crino, G. Giaccone, and G. Silvano et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer J Natl Cancer Inst 95 2003 1453 1461
12. R. Arriagada, B. Bergman, A. Dunant, T. Le Chevalier, J.P. Pignon, and J. Vansteenkiste Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 2004 351 360
13. R. Arriagada, A. Dunant, J.P. Pignon, B. Bergman, M. Chabowski, and D. Grunenwald et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer J Clin Oncol 28 2010 35 42
14. D. Waller, M.D. Peake, R.J. Stephens, N.H. Gower, R. Milroy, and M.K. Parmar et al. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial Eur J Cardiothorac Surg 26 2004 173 182
15. T. Winton, R. Livingston, D. Johnson, J. Rigas, M. Johnston, and C. Butts et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer N Engl J Med 352 2005 2589 2597
16. M.D. Vincent, C. Butts, L. Seymour, K. Ding, B. Graham, and P. Twumasi-Ankrah et al. Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC) (asbtr 7501) J Clin Oncol (Meeting Abstracts) 2009 27
17. J.Y. Douillard, R. Rosell, M. De Lena, F. Carpagnano, R. Ramlau, and J.L. Gonzales-Larriba et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial Lancet Oncol 7 2006 719 727
18. G.M. Strauss, J.E. Herndon 2nd, M.A. Maddaus, D.W. Johnstone, E.A. Johnson, and D.H. Harpole et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups J Clin Oncol 26 2008 5043 5051
19. J.P. Pignon, H. Tribodet, G.V. Scagliotti, J.Y. Douillard, F.A. Shepherd, and R.J. Stephens et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group J Clin Oncol 26 2008 3552 3559
20. R. Arriagada, A. Auperin, S. Burdett, J.P. Higgins, D.H. Johnson, and T. Le Chevalier et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data Lancet 375 2010 1267 1277
21. G.L. Colice, S. Shafazand, J.P. Griffin, R. Keenan, and C.T. Bolliger American College of Chest P. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines (2nd edition) Chest 132 2007 161S 177S
22. V. Puri, and B.F. Meyers Optimal initial pathologic mediastinal staging of lung cancer: EUS, EBUS, mediastinoscopy M.K. Ferguson, Difficult decisions in thoracic surgery 2011 Springer London 67 75
23. D.J. Boffa, A.S. Kosinski, S. Paul, J.D. Mitchell, and M. Onaitis Lymph node evaluation by open or video-assisted approaches in 11,500 anatomic lung cancer resections Ann Thorac Surg 94 2012 347 353
24. S.A. Defranchi, S.D. Cassivi, F.C. Nichols, M.S. Allen, K.R. Shen, and C. Deschamps et al. N2 disease in T1 non-small cell lung cancer Ann Thorac Surg 88 2009 924 928
25. D.J. Boffa, M.S. Allen, J.D. Grab, H.A. Gaissert, D.H. Harpole, and C.D. Wright Data from the Society of Thoracic Surgeons General Thoracic Surgery database: the surgical management of primary lung tumors J Thorac Cardiovasc Surg 135 2008 247 254
26. M.S. Allen, G.E. Darling, T.T. Pechet, J.D. Mitchell, J.E. Herndon 2nd, and R.J. Landreneau et al. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial Ann Thorac Surg 81 2006 1013 1019
27. A.G. Little, V.W. Rusch, J.A. Bonner, L.E. Gaspar, M.R. Green, and W.R. Webb et al. Patterns of surgical care of lung cancer patients Ann Thorac Surg 80 2005 2051 2056
28. R.J. Ginsberg, and L.V. Rubinstein Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group Ann Thorac Surg 60 1995 615 622
29. J. Donington, M. Ferguson, P. Mazzone, J. Handy Jr, M. Schuchert, and H. Fernando et al. American College of Chest Physicians and Society of Thoracic Surgeons consensus statement for evaluation and management for high-risk patients with stage I non-small cell lung cancer Chest 142 2012 1620 1635
30. M. Okada, W. Nishio, T. Sakamoto, K. Uchino, T. Yuki, and A. Nakagawa et al. Effect of tumor size on prognosis in patients with non-small cell lung cancer: the role of segmentectomy as a type of lesser resection J Thorac Cardiovasc Surg 129 2005 87 93
31. A. El-Sherif, H.C. Fernando, R. Santos, B. Pettiford, J.D. Luketich, and J.M. Close et al. Margin and local recurrence after sublobar resection of non-small cell lung cancer Ann Surg Oncol 14 2007 2400 2405
32. T. Chamogeorgakis, C. Ieromonachos, E. Georgiannakis, and D. Mallios Does lobectomy achieve better survival and recurrence rates than limited pulmonary resection for T1N0M0 non-small cell lung cancer patients? Interact Cardiovasc Thorac Surg 8 2009 364 372
33. D.P. Ceppa, A.S. Kosinski, M.F. Berry, B.C. Tong, D.H. Harpole, and J.D. Mitchell et al. Thoracoscopic lobectomy has increasing benefit in patients with poor pulmonary function: a Society of Thoracic Surgeons Database analysis Ann Surg 256 2012 487 493
34. R.R. Gopaldas, F.G. Bakaeen, T.K. Dao, G.L. Walsh, S.G. Swisher, and D. Chu Video-assisted thoracoscopic versus open thoracotomy lobectomy in a cohort of 13,619 patients Ann Thorac Surg 89 2010 1563 1570
35. G.E. Darling, M.S. Allen, P.A. Decker, K. Ballman, R.A. Malthaner, and R.I. Inculet et al. Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective American College of Surgeons Oncology Group Z0030 trial Chest 139 2011 1124 1129
36. W.D. Travis, E. Brambilla, M. Noguchi, A.G. Nicholson, K.R. Geisinger, and Y. Yatabe et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma J Thorac Oncol 6 2011 244 285
37. A. Yoshizawa, S. Sumiyoshi, M. Sonobe, M. Kobayashi, M. Fujimoto, and F. Kawakami et al. Validation of the IASLC/ATS/ERS lung adenocarcinoma classification for prognosis and association with EGFR and KRAS gene mutations: analysis of 440 Japanese patients J Thorac Oncol 8 2013 52 61
38. A. Yoshizawa, N. Motoi, G.J. Riely, C.S. Sima, W.L. Gerald, and M.G. Kris et al. Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases Mod Pathol 24 2011 653 664
39. F.C. Detterbeck, and R.J. Homer Approach to the ground-glass nodule Clin Chest Med 32 2011 799 810
40. N. Kothary, J.J. Heit, J.D. Louie, W.T. Kuo, B.W. Loo Jr, and A. Koong et al. Safety and efficacy of percutaneous fiducial marker implantation for image-guided radiation therapy J Vasc Interv Radiol 20 2009 235 239
41. R.W. Underberg, F.J. Lagerwaard, J.P. Cuijpers, B.J. Slotman, J.R. van Sornsen de Koste, and S. Senan Four-dimensional CT scans for treatment planning in stereotactic radiotherapy for stage I lung cancer Int J Radiat Oncol Biol Phys 60 2004 1283 1290
42. T. Kimura, Y. Hirokawa, Y. Murakami, M. Tsujimura, T. Nakashima, and Y. Ohno et al. Reproducibility of organ position using voluntary breath-hold method with spirometer for extracranial stereotactic radiotherapy Int J Radiat Oncol Biol Phys 60 2004 1307 1313
43. M. Guckenberger, T. Krieger, A. Richter, K. Baier, J. Wilbert, and R.A. Sweeney et al. Potential of image-guidance, gating and real-time tracking to improve accuracy in pulmonary stereotactic body radiotherapy Radiother Oncol 91 2009 288 295
44. J.M. Watkins, A.E. Wahlquist, A.J. Zauls, E.C. Fields, E. Garrett-Mayer, and E.G. Aguero et al. High-dose fractionated radiotherapy to 80 Gy for stage I-II medically inoperable non-small-cell lung cancer J Med Imaging Radiat Oncol 54 2010 554 561
45. X. Qiao, O. Tullgren, I. Lax, F. Sirzen, and R. Lewensohn The role of radiotherapy in treatment of stage I non-small cell lung cancer Lung Cancer 41 2003 1 11
46. R.C. McGarry, L. Papiez, M. Williams, T. Whitford, and R.D. Timmerman Stereotactic body radiation therapy of early-stage non-small-cell lung carcinoma: phase I study Int J Radiat Oncol Biol Phys 63 2005 1010 1015
47. A.J. Fakiris, R.C. McGarry, C.T. Yiannoutsos, L. Papiez, M. Williams, and M.A. Henderson et al. Stereotactic body radiation therapy for early-stage non-small-cell lung carcinoma: four-year results of a prospective phase II study Int J Radiat Oncol Biol Phys 75 2009 677 682
48. F.J. Lagerwaard, C.J. Haasbeek, E.F. Smit, B.J. Slotman, and S. Senan Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer Int J Radiat Oncol Biol Phys 70 2008 685 692
49. P. Baumann, J. Nyman, M. Hoyer, B. Wennberg, G. Gagliardi, and I. Lax et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy J Clin Oncol 27 2009 3290 3296
50. Y. Nagata, K. Takayama, Y. Matsuo, Y. Norihisa, T. Mizowaki, and T. Sakamoto et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame Int J Radiat Oncol Biol Phys 63 2005 1427 1431
51. R. Hara, J. Itami, T. Kondo, T. Aruga, T. Uno, and N. Sasano et al. Clinical outcomes of single-fraction stereotactic radiation therapy of lung tumors Cancer 106 2006 1347 1352
52. T. Xia, H. Li, Q. Sun, Y. Wang, N. Fan, and Y. Yu et al. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable stage I/II non-small-cell lung cancer Int J Radiat Oncol Biol Phys 66 2006 117 125
53. R. Timmerman, R. Paulus, J. Galvin, J. Michalski, W. Straube, and J. Bradley et al. Stereotactic body radiation therapy for inoperable early stage lung cancer JAMA 303 2010 1070 1076
54. S. Senthi, F.J. Lagerwaard, C.J. Haasbeek, B.J. Slotman, and S. Senan Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: a retrospective analysis Lancet Oncol 13 2012 802 809
55. S.M. Shirvani, J. Jiang, J.Y. Chang, J.W. Welsh, D.R. Gomez, and S. Swisher et al. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly Int J Radiat Oncol Biol Phys 84 2012 1060 1070
56. D. Palma, O. Visser, F.J. Lagerwaard, J. Belderbos, B.J. Slotman, and S. Senan Impact of introducing stereotactic lung radiotherapy for elderly patients with stage I non-small-cell lung cancer: a population-based time-trend analysis J Clin Oncol 28 2010 5153 5159
57. N.C. van der Voort van Zyp, J.B. Prevost, B. van der Holt, C. Braat, R.J. van Klaveren, and P.M. Pattynama et al. Quality of life after stereotactic radiotherapy for stage I non-small-cell lung cancer Int J Radiat Oncol Biol Phys 77 2010 31 37
58. F.J. Lagerwaard, N.K. Aaronson, C.M. Gundy, C.J. Haasbeek, B.J. Slotman, and S. Senan Patient-reported quality of life after stereotactic ablative radiotherapy for early-stage lung cancer J Thorac Oncol 7 2012 1148 1154
59. R.B. Barriger, J.A. Forquer, J.G. Brabham, D.L. Andolino, R.H. Shapiro, and M.A. Henderson et al. A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy Int J Radiat Oncol Biol Phys 82 2012 457 462
60. B.S. Hoppe, B. Laser, A.V. Kowalski, S.C. Fontenla, E. Pena-Greenberg, and E.D. Yorke et al. Acute skin toxicity following stereotactic body radiation therapy for stage I non-small-cell lung cancer: who's at risk? Int J Radiat Oncol Biol Phys 72 2008 1283 1286
61. M.N. Corradetti, A.R. Haas, and R. Rengan Central-airway necrosis after stereotactic body-radiation therapy N Engl J Med 366 2012 2327 2329
62. R. Timmerman, R. McGarry, C. Yiannoutsos, L. Papiez, K. Tudor, and J. DeLuca et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer J Clin Oncol 24 2006 4833 4839
63. N. Trakul, C.N. Chang, J. Harris, C. Chapman, A. Rao, and J. Shen et al. Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors Int J Radiat Oncol Biol Phys 84 2012 231 237
64. F.J. Lagerwaard, N.E. Verstegen, C.J. Haasbeek, B.J. Slotman, M.A. Paul, and E.F. Smit et al. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small-cell lung cancer Int J Radiat Oncol Biol Phys 83 2011 348 353
65. H. Onishi, H. Shirato, Y. Nagata, M. Hiraoka, M. Fujino, and K. Gomi et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys 81 2011 1352 1358
66. I.S. Grills, V.S. Mangona, R. Welsh, G. Chmielewski, E. McInerney, and S. Martin et al. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer J Clin Oncol 28 2010 928 935
67. C.W. Hurkmans, J.P. Cuijpers, F.J. Lagerwaard, J. Widder, U.A. van der Heide, and D. Schuring et al. Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study Radiat Oncol 4 2009 1
68. P.M. Ellis, N. Blais, D. Soulieres, D.N. Ionescu, M. Kashyap, and G. Liu et al. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer J Thorac Oncol 6 2011 1379 1391
69. K.A. Olaussen, A. Dunant, P. Fouret, E. Brambilla, F. Andre, and V. Haddad et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 2006 983 991
70. M. Filipits, V. Haddad, K. Schmid, A. Huynh, A. Dunant, and F. Andre et al. Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program Clin Cancer Res 13 2007 3892 3898
71. M. Filipits, R. Pirker, A. Dunant, S. Lantuejoul, K. Schmid, and A. Huynh et al. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program J Clin Oncol 25 2007 2735 2740
72. R. Pirker, M. Filipits, A. Dunant, J.P. Pignon, J.C. Soria, and E. Brambilla et al. IALT-Bio: a challenging research to improve adjuvant chemotherapy of completely resected NSCLC: D3-03 J Thorac Oncol 2 2007 S397 S398
73. E. Brambilla, J.C. Soria, V. Haddad, S. Lantuejoul, F. Andre, and M. Filipits et al. Prognostic and predictive value of apoptosis related factors Fas, FasL and survivin in non small cell lung carcinoma patients enrolled in the IALT Trial: PD2-3-4 J Thorac Oncol 2 2007 S444 S445
74. N.S. Kamal, J.C. Soria, J. Mendiboure, D. Planchard, K.A. Olaussen, and V. Rousseau et al. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer Clin Cancer Res 16 2010 1206 1215
75. P. Seve, R. Lai, K. Ding, T. Winton, C. Butts, and J. Mackey et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10 Clin Cancer Res 13 2007 994 999
76. M.S. Tsao, S. Aviel-Ronen, K. Ding, D. Lau, N. Liu, and A. Sakurada et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer J Clin Oncol 25 2007 5240 5247
77. F.A. Shepherd, C. Domerg, P. Hainaut, P.A. Janne, J.P. Pignon, and S. Graziano et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy J Clin Oncol 31 2013 2173 2181
78. B. Besse, K.A. Olaussen, and JC. Soria ERCC1 and RRM1: ready for prime time? J Clin Oncol 31 2013 1050 1060
79. Z. Zheng, T. Chen, X. Li, E. Haura, A. Sharma, and G. Bepler DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer N Engl J Med 356 2007 800 808
80. R.A. Hubner, R.D. Riley, L.J. Billingham, and S. Popat Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations PLoS One 6 2011 e25164
81. C. Mascaux, M.W. Wynes, Y. Kato, C. Tran, B.R. Asuncion, and J.M. Zhao et al. EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor - a novel antibody for immunohistochemistry or AQUA technology Clin Cancer Res 17 2011 7796 7807
82. A. McCabe, M. Dolled-Filhart, R.L. Camp, and D.L. Rimm Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis J Natl Cancer Inst 97 2005 1808 1815
83. L. Friboulet, K.A. Olaussen, J.P. Pignon, F.A. Shepherd, M.S. Tsao, and S. Graziano et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer N Engl J Med 368 2013 1101 1110
84. J.-C. Soria, F. Barlesi, B. Besse, J. Mazieres, P. Merle, and J. Cadranel et al. Results of the prospective, randomized, and customized NSCLC adjuvant phase II trial (IFCT-0801, TASTE trial) from the French Collaborative Intergroup (abstr 7505) J Clin Oncol (Meeting Abstracts) 2013 31
85. G. Bepler, J. Moon, R. Zinner, R. Calhouri, K. Kernstine, and C. Williams et al. Customized adjuvant chemotherapy prognostic and predictive factors (abstract 77IN) Ann Oncol 2012 23:ix49-50
86. R. Zinner, G. Bepler, J. Moon, R.F. Calhoun, K.H. Kernstine, and P. Mack et al. O28.08 Biomarker (ERCC1 and RRM1)-based decision-making algorithm for adjuvant chemotherapy in stage I non-small-cell lung cancer (NSCLC) (SWOG-0720, NCT00792701) Presented at: 14th World Conference on Lung Cancer 2011 July 6 (Amsterdam, Netherlands)
87. S. Novello, C. Manegold, C. Grohe, I. Colantonio, M.H. Serke, and M. Geissler et al. International tailored chemotherapy adjuvant trial: Itaca trial (abstract TPS7109) J Clin Oncol (Meeting Abstracts) 30 2012
88. M. Kreuter, J. Vansteenkiste, F. Griesinger, H. Hoffmann, H. Dienemann, and P. De Leyn et al. Trial on refinement of early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: the TREAT protocol BMC Cancer 7 2007 77
89. T. Nakagawa, Y. Otake, K. Yanagihara, R. Miyahara, S. Ishikawa, and M. Fukushima et al. Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC) Lung Cancer 43 2004 145 149
90. Y. Shintani, M. Ohta, H. Hirabayashi, H. Tanaka, K. Iuchi, and K. Nakagawa et al. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction Int J Cancer 104 2003 790 795
91. R. Klopfleisch, A.T. Weiss, and A.D. Gruber Excavation of a buried treasure - DNA, mRNA, miRNA and protein analysis in formalin fixed, paraffin embedded tissues Histol Histopathol 26 2011 797 810
92. C. Vogel, and E.M. Marcotte Insights into the regulation of protein abundance from proteomic and transcriptomic analyses Nat Rev Genet 13 2012 227 232
93. G. Bepler, C. Williams, M.J. Schell, W. Chen, Z. Zheng, and G. Simon et al. Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer J Clin Oncol. Epub 2013 May 22 10.1200/jco.2012.46.978310.1200/jco.2012. 46.9783. Available from: http://jco.ascopubs.org
94. J.E. Quinn, R.D. Kennedy, P.B. Mullan, P.M. Gilmore, M. Carty, and P.G. Johnston et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis Cancer Res 63 2003 6221 6228
95. B. Massuti, U. Jimenez, J.M. Rodriguez Paniagua, Y.W. Pun, M. Cobo, and E. Carcereny Costa et al. SCAT trial: phase III Spanish customized adjuvant treatment according BRCA1 mRNA levels in stage II-IIIA non-small cell lung cancer (abstract TPS208) J Clin Oncol (Meeting Abstracts) 29 2011
96. J.M. Sanchez, M. Cobo, R. Arrabal, B. Massuti, J.M. Rodriguez Paniagua, and T. Moran et al. Pilot SCAT trial: Spanish customized adjuvant chemotherapy (CT) based on BRCA1 mRNA expression levels (l) in resected stage II-IIIA non-small cell lung cancer (NSCLC) patients (abstract 7011) J Clin Oncol (Meeting Abstracts) 30 2012
97. T. Moran, M. Cobo, M. Domine, M. Sanchez-Ronco, I. Bover, M. Provencio Interim analysis of the Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized therapy in advanced non-small cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC) (abstract LBA8002) J Clin Oncol (Meeting Abstracts) 31 2013
98. A. Sandler, R. Gray, M.C. Perry, J. Brahmer, J.H. Schiller, and A. Dowlati et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
99. H.A. Wakelee, S.E. Dahlberg, S.M. Keller, D.R. Gandara, S.L. Graziano, and N.B. Leighl et al. O42.03 Interim report of on-study demographics and toxicity from Eastern Cooperative Oncology Group (ECOG) E1505, a phase III randomized trial of adjuvant chemotherapy with or without bevacizumab for completely resected early stage non-small cell lung cancer (NSCLC) Presented at: 14th World Conference on Lung Cancer 2011 July 7 (Amsterdam, Netherlands)
100. H.A. Wakelee, S.E. Dahlberg, S.M. Keller, D.R. Gandara, S.L. Graziano, and N.B. Leighl et al. Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC) (abstract 7013) J Clin Oncol (Meeting Abstracts) 29 2011
101. E. De Plaen, K. Arden, C. Traversari, J.J. Gaforio, J.P. Szikora, and C. De Smet et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family Immunogenetics 40 1994 360 369
102. P. Tyagi, and B. Mirakhur MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy Clin Lung Cancer 10 2009 371 374
103. J.-H. Kim, J.I. Zo, H. Nakayama, T. De Pas, J. Dahabreh, and M. Zielinski et al. MO21.08 Patient and tumor characteristics impacting on MAGE-A3 expression: screening data from the MAGRIT phase III trial Presented at: 14th World Conference of Lung Cancer 2011 July 7 (Amsterdam, Netherlands)
104. J. Vansteenkiste, M. Zielinski, A. Linder, J. Dahabreh, E.E. Gonzalez, and W. Malinowski et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results J Clin Oncol. Epub 2013 May 30 10.1200/jco.2012.43.7103. Available from: http://jco.ascopubs.org
105. S. Peters, W. Weder, P. Meldgaard, K.J. O'Byrne, A. Wrona, and C. Dooms et al. The European Thoracic Oncology Platform Lungscape project: clinical outcome data as a basis for molecular correlations in resected non-small cell lung cancer (abstr 7514) J Clin Oncol (Meeting Abstracts) 31 2013
106. F. Barlesi, H. Blons, M. Beau-Faller, I. Rouquette, L. Ouafik, and J. Mosser et al. Biomarkers (BM) France: Results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non-small cell lung cancer (NSCLC) patients (pts) (abstract 8000) J Clin Oncol (Meeting Abstracts) 31 2013
107. B.E. Johnson, M.G. Kris, L.D. Berry, D.J. Kwiatkowski, A.J. Iafrate, and M. Varella-Garcia et al. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC) (abstr 8019) J Clin Oncol (Meeting Abstracts) 31 2013
108. G. Giaccone, A. Lopez-Chavez, A. Thomas, A. Rajan, M. Raffeld, and R.N. Duffy et al. Custom (molecular profiling and targeted therapy for advanced non-small cell lung cancer, small cell lung cancer, and thymic malignancies) trial (abstract 7513) J Clin Oncol 31 2013
109. Kerr KN, Dafni U, O'Byrne K, Dooms C, Marchetti A, Sasano I, et al. ALK immunohistochemistry and fluorescence in-situ hybridization in Lung adenocarcinomas from the ETOP Lungscape tumour cohort. Presented at: 15th World Conference of Lung Cancer. 2013 October 28 (Sydney, Australia).
110. S.M. Ali, N.A. Palma, K. Wang, J.S. Ross, P.J. Stephens, and R. Yelensky et al. Clinical next generation sequencing (NGS) to reveal high frequency of alterations to guide targeted therapy in lung cancer patients (abstract 8020) J Clin Oncol (Meeting Abstracts) 31 2013
111. T. Mitsudomi, S. Morita, Y. Yatabe, S. Negoro, I. Okamoto, and J. Tsurutani et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
112. C. Zhou, Y.L. Wu, G. Chen, J. Feng, X.Q. Liu, and C. Wang et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742
113. R. Rosell, E. Carcereny, R. Gervais, A. Vergnenegre, B. Massuti, and E. Felip et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
114. T.S. Mok, Y.L. Wu, S. Thongprasert, C.H. Yang, D.T. Chu, and N. Saijo et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
115. Y.Y. Janjigian, B.J. Park, M.F. Zakowski, M. Ladanyi, W. Pao, and S.P. D'Angelo et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations J Thorac Oncol 6 2011 569 575
116. S.P. D'Angelo, Y.Y. Janjigian, N. Ahye, G.J. Riely, J.E. Chaft, and C.S. Sima et al. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib J Thorac Oncol 7 2012 1815 1822
117. M. Tsuboi, H. Kato, K. Nagai, R. Tsuchiya, H. Wada, and H. Tada et al. Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer Anticancer Drugs 16 2005 1123 1128
118. G.D. Goss, I. Lorimer, M.S. Tsao, C.J. O'Callaghan, K. Ding, and G.A. Masters et al. A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinb in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19 (LBA7005) J Clin Oncol (Meeting Abstracts) 28 2010
119. N. Thatcher, A. Chang, P. Parikh, J. Rodrigues Pereira, T. Ciuleanu, and J. von Pawel et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537
120. K. Kelly, K. Chansky, L.E. Gaspar, K.S. Albain, J. Jett, and Y.C. Ung et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023 J Clin Oncol 26 2008 2450 2456
121. F. Richardson, K. Richardson, D. Young, R. Sennello, J. Horan, and A. Davies et al. O28.01 select biomarker analyses of completely resected NSCLC tumors from enrolled patients in an adjuvant erlotinib (Tarceva) clinical trial (RADIANT) Presented at: 14th World Conference on Lung Cancer 2011 July 6 (Amsterdam, Netherlands)
122. J.W. Neal, N.A. Pennell, R. Govindan, M. Lanuti, R.P. Greenerger Rosovsky, and R.S. Heist et al. The SELECT study: a multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) (abstract 7010) J Clin Oncol (Meeting Abstracts) 30 2012
123. H. Tada, K. Takeda, K. Nakagawa, I. Okamoto, T. Mitsudomi, and Y. Ichinose et al. Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer haboring activating EGFR mutation (WJOG6410L) (abstract TPS7110) J Clin Oncol (Meeting Abstracts) 30 2012
124. Govindan R. Lung cancer: molecular profiling and genomics. Presented at: ASCO Annual Meeting; 2013 May 31; Chicago, IL.
125. C.Q. Zhu, K. Ding, D. Strumpf, B.A. Weir, M. Meyerson, and N. Pennell et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer J Clin Oncol 28 2010 4417 4424